Online inquiry

IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ700MR)

This product GTTS-WQ700MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL17A&TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002190.3; NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 7124
UniProt ID Q16552; P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ700MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12096MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ13055MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ11MR IVTScrip™ mRNA-Anti-S, 2130(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 2130
GTTS-WQ14469MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ3100MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ14737MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ12516MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ13546MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRX-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW